Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis: Phase 3 Long-Term Data-MedSci.cn

Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis: Phase 3 Long-Term Data

Kulasekararaj, A; Griffin, M; Piatek, CI; Shammo, J; Nishimura, JI; Patriquin, CJ; Schrezenmeier, H; Gaya, A; Patel, Y; Liu, P; Filippov, G; De Fontbrune, FS; Risitano, AM; Lee, JW

BLOOD, 2023; 142 ():

科室
- - 订阅+
  - 更多科室
工具
服务